

**PERSONAL
INFORMATIONS**

Chiara Agrati



Sex Female | Birth day 01/06/1974 | Nationality Italian

ACTUAL POSITION

Head of the Laboratory of Cellular Immunology and Pharmacology

**PROFESSIONAL
EXPERIENCE**

-
- Jul 2016 - today Head of the Cellular Immunology and Pharmacology Laboratory
 - Jan 2008 – Jul 2016 Biologist, Permanent staff
INMI “Lazzaro Spallanzani” - I.R.C.C.S., Laboratory di Virologia, INMI “L. Spallanzani”
 - Apr 2007 – Dec 2007 Researcher
INMI “Lazzaro Spallanzani” - I.R.C.C.S., Laboratory of Cellular Immunology
Projects: Emerging infectious diseases; cytokine storm, influenza cross-immunity
 - Apr 2006 – Apr 2007 Researcher
INMI “Lazzaro Spallanzani” - I.R.C.C.S., Laboratory of Cellular Immunology
Projects: Emerging infectious diseases; cytokine storm, set up diagnostic tests, influenza cross-immunity
 - Apr 2005 – Mar 2006 Researcher
INMI “Lazzaro Spallanzani” - I.R.C.C.S., Laboratory of Cellular Immunology
Projects: Cross talk between innate and adaptive cells during chronic infections; analysis of immune reconstitution in chronic HIV patients; gammadelta t cell immunity against emerging viruses (SARS-CoV and orthopoxviruses).
 - Apr 2004 – Jun 2004 Researcher, temporary staff
INMI “Lazzaro Spallanzani” - I.R.C.C.S., Laboratory of Virology
Projects: SARS emergency; Support for SARS emergency diagnostics. Set up of immunological test to evaluate the antigen specific T cell response.
 - Jan 2004- Mar 2005 Researcher
INMI “Lazzaro Spallanzani” - I.R.C.C.S., Laboratory of Cellular Immunology
Project: Innate immune response during HCV infection
 - Dec 2001 – Dec 2003 Researcher
INMI “Lazzaro Spallanzani” - I.R.C.C.S., Laboratory of Cellular Immunology
European Project: n.QLK2-CT-1999 entitled “TB vaccin cluster”

- Jul 1998 – Nov 2001 Researcher
INMI “Lazzaro Spallanzani” - I.R.C.C.S., Laboratory of Cellular Immunology
Projects: Immune response to chronic viral infections (HIV, HCV), inflammation, innate immunity.
- Nov 1996 – Giu 1998 Researcher
University of Rome “La Sapienza”
Project: Muscarinic receptor characterization on neurons

EDUCATION AND TRAINING

- 2019 Cell Sorting: “MACS-Quant Tyto”-
 Colonia, Germany
- 2018 Multiparametric flow cytometry: new applications
 INMI L Spallanzani
- 2007 Hand-on course for handling class 4 agents
 INMI L. Spallanzani - IRCCS
- 2007 International High Containment Biosafety Workshop
 Canadian Science Centre for Human and Animal Health, Winnipeg, Manitoba, Canada
- 2007 PhD in Immunology
 University of Rome, “Tor Vergata”
- 2006 Development and commercial production of standardized PCR-assays for
 detection of viral hemorrhagic fever viruses and their implementation in the
 diagnostic service of EU P4 laboratories
 Hamburg
- 2003 Specialty degree in Medical Microbiology and Virology – 50/50 e lode
 Università di Roma “Tor Vergata”
- 1998 Degree in Biology– 110/110 e lode
 Università di Roma “La Sapienza”

COURSE FOR UNIVERSITY STUDENTS

Dr Agrati contributed to University course by presenting data on hot topics about infectious diseases.

- 2019** - Master II level in Molecular Virology (University “Sapienza”)

- 2018** - Master II level in Molecular Virology (University “Sapienza”)
- 2017** - Master II level in Molecular Virology (University “Sapienza”)
- Course “HIV: conoscere per prevenire”
- 2016** - Master II level in Molecular Virology (University “Sapienza”)
- Course “Ebola: protective and pathogenetic mechanisms “
- Course “HIV: conoscere per prevenire”
- 2015** - Master II level in Molecular Virology (University “Sapienza”)
- Course “Ebola: protective and pathogenetic mechanisms “

PROFESSIONAL PROFILE

Dr. Chiara Agrati has a PhD in Immunology and she is specialized in Microbiology and Virology. Since 2016, Chiara Agrati is the head of the Cellular Immunology Laboratory at INMI Lazzaro Spallanzani in Rome where she is in charge of diagnostic and research activity on immune response to viral diseases. She has a longstanding experience (more than 20 years) in the study of the immune response to chronic (HIV, HCV infection) and emerging pathogens (SARS-CoV, Ebola, pandemic flu, SARS-CoV2). Her research activities are mainly focused to the analysis of the protection/pathogenetic mechanisms driven by innate immune response to viral infection as well as to the dissection of the cross-talk between innate and adaptive immune responses.

In chronic infections, she described the impairment of $\gamma\delta$ T cells during HIV infection, she identified the mechanisms responsible for this immunological defect and she was involved in defining the possible use of $\gamma\delta$ T cells as a target in immunotherapy for HIV infection. She identified a functional marker of CD4 T cells associated with a worse immune-recovery and she described the main role of cross-talk among dendritic cells and $\gamma\delta$ T cells in the generation of a protective immunity.

Moreover, Dr Agrati was involved in several projects on emerging viral infections. She identified gammadelta T cells as main actor in shaping the protective immune response to SARS-CoV infection, and she described their ability to kill cells infected with SARS-CoV, orthopoxvirus as well as with Zika virus. During the emergence related to Ebola infection, she participated to the task force of clinicians and researchers and she described a dramatic impairment of adaptive T cell response during acute Ebola infection, resulting in the reactivation of herpesvirus. She has a good experience in working in BSL3/4 laboratory.

In the last few months, she focused on the COVID-19 patients aimed to define the impact of inflammation observed in patients with severe infection on immune response and in testing the role of regulatory cells in the clinical outcome.

In addition, she successfully administered scientific projects, collaborated with other research groups, and produced several peer-reviewed publications from each project.

Author of more than 100 publications indexed on PubMed, cited on ISI Web of Knowledge

Grants

- 2020: Grant COVID-19 COVID-2020-12371735 “The double-edged role of innate immunity in SARS-CoV-2 infection: Dissecting new potential therapeutic targets”, Principal Investigator of Operative Unit
 - 2018: Grant “EXO-DAA” (funded by Regione Lazio), Principal Investigator
 - 2018: European Union's Horizon 2020 nell'ambito delle azioni Marie Skłodowska–Curie. “BE a citizEn Scientis”, Principal Investigator of Operative Unit
 - 2016: European Union's Horizon 2020: “European HIV Alliance (EHVA)”, key personnel
 - 2010: Ricerca Finalizzata (RF-2010 – 2310899, UO 3): “Campylobacter, L. monocytogenes ed E. coli produttori di Verocitotossine (VTEC) in Italia: un approccio di epidemiologia molecolare per identificare le fonti di infezione e i fattori di rischio per l'esposizione umana”, Principal Investigator of Operative Unit
 - 2003: Ricerca Finalizzata (UO 7): “Alterazioni linfomonocitarie indotte dal SARS coronavirus) in seno al progetto Aspetti diagnostici, patogenetici ed epidemiologici delle infezioni virali del tratto respiratorio”, Principal Investigator of Operative Unit
- 2003: Ricerca Finalizzata (RF03.120, UO 3): “Interazione immunità naturale-specifica nell'infezione da HCV: ricerca di nuovi bersagli terapeutici”, Principal Investigator of Operative Unit

PERSONELL SKILLS

LANGUAGES:

	COMPEHENSION		SPEACKING		WRITING
	Listening	Reading	Interaction	Oral Production	
Inglese	B1	B2	B1	B1	B1
Francese	B1	B1	B1	B1	B1

Informatic skills

- Windows**
- Microsoft Word
 - Excel
 - Power Point
 - Access
 - GraphPadPrism
 - Reference Manager
- Macintosh**
- Cell Quest
 - Flow Jo
 - Claris Work
 - Spice

OTHER RESEARCH ACTIVITIES

- Referee** She is referee for several international journals (Scientific Reports, Journal of Virology, Frontiers in Immunology, Clinical Infectious Diseases, J Infectious Diseases e altri).
- Editorial board** She is Editor for “Scientific Reports” and for “Cell Death and Discovery”
- Scientific activities** From 2017, she is involved in the scientific organization of the congress ICAR
From 2019 she is involved in the Technical-Scientific committee of the INMI L Spallanzani
- Scientific Organization** Ordine Nazionale dei Biologi (numero d'ordine: 050846 dal 30.05.01).

Publications

1. Mondì A, Lorenzini P, Castillettì C, Gagliardini R, Lalle E, Corpolongo A, Valli MB, Taglietti F, Cicalini S, Loiacono L, Di Gennaro F, D'Offizi G, Palmieri F, Nicastrì E, **Agrati C**, Petrosillo N, Ippolito G, Vaia F, Girardi E, Capobianchi MR, Antinori A; INMI Recovery study group. Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted in an Italian Reference Hospital. *Int J Infect Dis.* 2021 Mar 3:S1201-9712(21)00203-4. doi: 10.1016/j.ijid.2021.02.117. Online ahead of print.
2. Andreano E, Nicastrì E, Paciello I, Pileri P, Manganaro N, Piccini G, Manenti A, Pantano E, Kabanova A, Troisi M, Vacca F, Cardamone D, De Santi C, Torres JL, Ozorowski G, Benincasa L, Jang H, Di Genova C, Depau L, Brunetti J, **Agrati C**, Capobianchi MR, Castillettì C, Emiliozzi A, Fabbiani M, Montagnani F, Bracci L, Sautto G, Ross TM, Montomoli E, Temperton N, Ward AB, Sala C, Ippolito G, Rappuoli R. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. *Cell.* 2021 Feb 23:S0092-8674(21)00224-5. doi: 10.1016/j.cell.2021.02.035. Online ahead of print
3. Bordoni V, Tartaglia E, Sacchi A, Fimia GM, Cimini E, Casetti R, Notari S, Grassi G, Marchioni L, Bibas M, Capobianchi MR, Locatelli F, Maeurer M, Zumla A, Antinori A, Nicastrì E, Ippolito G, **Agrati C**. The unbalanced p53/SIRT1 axis may impact lymphocyte homeostasis in COVID-19 patients. *Int J Infect Dis.* 2021 Feb 10;105:49-53. doi: 10.1016/j.ijid.2021.02.019. Online ahead of print.
4. Colavita F, Lapa D, Carletti F, Lalle E, Messina F, Rueca M, Matusali G, Meschi S, Bordini L, Marsella P, Nicastrì E, Marchioni L, Mariano A, Scorzolini L, Ascoli Bartoli T, Di Caro A, Ippolito G, Capobianchi MR, Castillettì C; INMI COVID-19 Laboratory Team and **INMI COVID-19 Study Group**. Virological Characterization of the First 2 COVID-19 Patients Diagnosed in Italy: Phylogenetic Analysis, Virus Shedding Profile From Different Body Sites, and Antibody Response Kinetics. *Open Forum Infect Dis.* 2020 Sep 2;7(10):ofaa403. doi: 10.1093/ofid/ofaa403. eCollection 2020 Oct
5. Carsetti R, Zaffina S, Piano Mortari E, Terreri S, Corrente F, Capponi C, Palomba P, Mirabella M, Cascioli S, Palange P, Cuccaro I, Milito C, Zumla A, Maeurer M, Camisa V, Vinci MR, Santoro A, Cimini E, Marchioni L, Nicastrì E, Palmieri F, **Agrati C**, Ippolito G, Porzio O, Concato C, Onetti Muda A, Raponi M, Quintarelli C, Quinti I, Locatelli F. Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases. *Front Immunol.* 2020 Dec 16;11:610300. doi: 10.3389/fimmu.2020.610300. eCollection 2020
6. Lanini S, Montaldo C, Nicastrì E, Vairo F, **Agrati C**, Petrosillo N, Scognamiglio

- P, Antinori A, Puro V, Di Caro A, De Carli G, Navarra A, Agresta A, Cimaglia C, Palmieri F, D'Offizi G, Marchioni L, Kobinger GP, Maeurer M, Girardi E, Capobianchi MR, Zumla A, Locatelli F, Ippolito G. COVID-19 disease-Temporal analyses of complete blood count parameters over course of illness, and relationship to patient demographics and management outcomes in survivors and non-survivors: A longitudinal descriptive cohort study. *PLoS One*. 2020 Dec 28;15(12):e0244129. doi: 10.1371/journal.pone.0244129. eCollection 2020.
7. Frustaci A, Alfarano M, Verardo R, Agrati C, Casetti R, Miraldi F, Galea N, Letizia C, Chimenti C. Myocarditis-associated necrotizing coronary vasculitis: incidence, cause, and outcome. *Eur Heart J*. 2020 Dec 23;ehaa973. doi: 10.1093/eurheartj/ehaa973. Online ahead of print
 8. Calò Carducci FI, De Ioris MA, **Agrati C**, Carsetti R, Perrotta D, D'Argenio P, De Benedetti F, Notari S, Rossi P, Campana A. Hyperinflammation in Two Severe Acute Respiratory Syndrome Coronavirus 2-Infected Adolescents Successfully Treated With the Interleukin-1 Inhibitor Anakinra and Glucocorticoids. *Front Pediatr*. 2020 Nov 30;8:576912. doi: 10.3389/fped.2020.576912. eCollection 2020
 9. Vita S, Di Bari V, Corpolongo A, Goletti D, Espinosa J, Petracca S, Palmieri F, Nicastrì E; **INMI COVID-19 study groups**. Down Syndrome patients with COVID-19 pneumonia: A high-risk category for unfavourable outcome. *Int J Infect Dis*. 2021 Feb;103:607-610. doi: 10.1016/j.ijid.2020.11.188. Epub 2020 Nov 30
 10. Oliverio S, Beltran JSO, Occhigrossi L, Bordoni V, **Agrati C**, D'Eletto M, Rossin F, Borelli P, Amarante-Mendes GP, Demidov O, Barlev NA, Piacentini M. Transglutaminase Type 2 is Involved in the Hematopoietic Stem Cells Homeostasis. *Biochemistry (Mosc)*. 2020 Oct;85(10):1159-1168. doi: 10.1134/S0006297920100041
 11. Del Nonno F, Frustaci A, Verardo R, Chimenti C, Nicastrì E, Antinori A, Petrosillo N, Lalle E, **Agrati C**, Ippolito G; INMI COVID study group. Virus-Negative Myopericarditis in Human Coronavirus Infection: Report From an Autopsy Series. *Circ Heart Fail*. 2020 Nov 12;13(11):CIRCHEARTFAILURE120007636. doi:
 12. Antonioli M, Pagni B, Vescovo T, Ellis R, Cosway B, Rollo F, Bordoni V, **Agrati C**, Labus M, Covello R, Benevolo M, Ippolito G, Robinson M, Piacentini M, Lovat P, Fimia GM. HPV sensitizes OPSCC cells to cisplatin-induced apoptosis by inhibiting autophagy through E7-mediated degradation of AMBRA1. *Autophagy*. 2020 Nov 23:1-14. doi: 10.1080/15548627.2020.1847444. Online ahead of print
 13. Sacchi A, Grassi G, Bordoni V, Lorenzini P, Cimini E, Casetti R, Tartaglia E, Marchioni L, Petrosillo N, Palmieri F, D'Offizi G, Notari S, Tempestilli M, Capobianchi MR, Nicastrì E, Maeurer M, Zumla A, Locatelli F, Antinori A, Ippolito G, **Agrati C**. Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome. *Cell Death Dis*. 2020 Oct 27;11(10):921. doi: 10.1038/s41419-020-03125-1.
 14. Mondì A, Cimini E, Colavita F, Cicalini S, Pinnetti C, Matusali G, Casetti R, Maeurer M, Vergori A, Mazzotta V, Gagliardini R, De Zottis F, Schinina V, Girardi E, Puro V, Ippolito G, Vaia F, Capobianchi MR, Castillette C, **Agrati C**, Antinori A. COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2. *J Med Virol*. 2021 Mar;93(3):1796-1804. doi: 10.1002/jmv.26556. Epub 2020 Oct 8
 15. Pinnetti C, Vergori A, **Agrati C**, Castillette C, Campioni P, Gagliardini R, Mondì A, Notari S, Amendola A, Cicalini S, Baldini F, Capobianchi MR, Antinori A. SARS-CoV-2 infection does not induce HIV viral escape in the central nervous system: A case series. *Int J Infect Dis*. 2020 Dec;101:38-41. doi: 10.1016/j.ijid.2020.09.040. Epub 2020 Sep 17
 16. **Agrati C**, De Biasi S, Fidanza L, Gibellini L, Nasi M, Pinti M, Cossarizza A. The importance of advanced cytometry in defining new immune cell types and

- functions relevant for the immunopathogenesis of HIV infection. *AIDS*. 2020 Dec 1;34(15):2169-2185. doi: 10.1097/QAD.0000000000002675
17. Bordoni V, Tartaglia E, Refolo G, Sacchi A, Grassi G, Antinori A, Fimia GM, **Agrati C**. Per2 Upregulation in Circulating Hematopoietic Progenitor Cells During Chronic HIV Infection. *Front Cell Infect Microbiol*. 2020 Jul 21;10:362. doi: 10.3389/fcimb.2020.00362. eCollection 2020
 18. de Sousa E, Ligeiro D, Lérias JR, Zhang C, **Agrati C**, Osman M, El-Kafrawy SA, Azhar EI, Ippolito G, Wang FS, Zumla A, Maeurer M. Mortality in COVID-19 disease patients: Correlating the association of major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (SARS-CoV-2) variants. *Int J Infect Dis*. 2020 Sep;98:454-459. doi: 10.1016/j.ijid.2020.07.016. Epub 2020 Jul 18
 19. **Agrati C**, Mazzotta V, Pinnetti C, Biava G, Bibas M. Venous thromboembolism in people living with HIV infection (PWH). *Transl Res*. 2021 Jan;227:89-99. doi: 10.1016/j.trsl.2020.07.007. Epub 2020 Jul 18.
 20. Song JW, Zhang C, Fan X, Meng FP, Xu Z, Xia P, Cao WJ, Yang T, Dai XP, Wang SY, Xu RN, Jiang TJ, Li WG, Zhang DW, Zhao P, Shi M, **Agrati C**, Ippolito G, Maeurer M, Zumla A, Wang FS, Zhang JY. Immunological and inflammatory profiles in mild and severe cases of COVID-19. *Nat Commun*. 2020 Jul 8;11(1):3410. doi: 10.1038/s41467-020-17240-2
 21. Tempestilli M, Caputi P, Avataneo V, Notari S, Forini O, Scorzolini L, Marchioni L, Ascoli Bartoli T, Castilletti C, Lalle E, Capobianchi MR, Nicastrì E, D'Avolio A, Ippolito G, **Agrati C**. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. *J Antimicrob Chemother*. 2020 Jul 1:dkaa239. doi: 10.1093/jac/dkaa239. Online ahead of print. PMID: 32607555
 22. Messina F, Giombini E, **Agrati C**, Vairo F, Ascoli Bartoli T, Al Moghazi S, Piacentini M, Locatelli F, Kobinger G, Maeurer M, Zumla A, Capobianchi MR, Lauria FN, Ippolito G. COVID-19: viral-host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection. COVID 19 INMI Network Medicine for IDs Study Group. Version 2. *J Transl Med*. 2020 Jun 10;18(1):233. doi: 10.1186/s12967-020-02405-w. PMID: 32522207 Free PMC article.
 23. Ramalho R, Rao M, Zhang C, **Agrati C**, Ippolito G, Wang FS, Zumla A, Maeurer M. Immunometabolism: new insights and lessons from antigen-directed cellular immune responses. *Semin Immunopathol*. 2020 Jun;42(3):279-313. doi: 10.1007/s00281-020-00798-w. Epub 2020 Jun 9. PMID: 32519148 Free PMC article. Review
 24. **Agrati C**, Sacchi A, Bordoni V, Cimini E, Notari S, Grassi G, Casetti R, Tartaglia E, Lalle E, D'Abramo A, Castilletti C, Marchioni L, Shi Y, Mariano A, Song JW, Zhang JY, Wang FS, Zhang C, Fimia GM, Capobianchi MR, Piacentini M, Antinori A, Nicastrì E, Maeurer M, Zumla A, Ippolito G. *Cell Death Differ*. 2020 Jun 8:1-12. doi: 10.1038/s41418-020-0572-6. Online ahead of print. Chiara Agrati, Alessandra Sacchi, Veronica Bordoni, Eleonora Cimini, Stefania Notari, Germana Grassi, Rita Casetti, Eleonora Tartaglia, Eleonora Lalle1, Alessandra D'Abramo, Concetta Castilletti, Yufang Shi, Andrea Mariano, Jin-Wen Song, Ji-Yuan Zhang, Fu-Sheng Wang, Chao Zhang, Gian Maria Fimia, Maria R. Capobianchi, Mauro Piacentini, Emanuele Nicastrì, Markus Maeurer, Alimuddin Zumla, and Giuseppe Ippolito. Expansion of myeloid derived suppressor cells in patients with severe Coronavirus Disease (COVID-2019). *Cell Death and Diff*. In press
 25. Zumla A, Wang FS, Ippolito G, Petrosillo N, **Agrati C**, Azhar EI, El-Kafrawy SA, Osman M, Zitzvogel L, Locatelli F, Gorman E, O'Kane C, Mcauley D, Maeurer M. Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - achieving global consensus and visibility for cellular host-directed therapies. *Int J Infect Dis*. 2020 May 17.
 26. Frustaci A, Scarpa M, Maria da Rioli R, **Agrati C**, Finato N, Verardo R, Grande C, Chimenti C, Nora C, Russo MA, Livi U. Fabry cardiomyopathy: Gb3-

- induced auto-reactive panmyocarditis requiring heart transplantation. *ESC Heart Fail.* 2020 Apr 29.
27. Veronica Bordoni, Alessandra Sacchi, Eleonora Cimini, Stefania Notari, Germana Grassi, Eleonora Tartaglia, Rita Casetti, Letizia Giancola, Nazario Bevilacqua, Markus Maeurer, Alimuddin Zumla, Franco Locatelli, Fabrizio De Benedetti, Fabrizio Palmieri, Luisa Marchioni, Maria R Capobianchi, Gianpiero D'Offizi, Nicola Petrosillo, Andrea Antinori, Emanuele Nicastrì, Giuseppe Ippolito, **Chiara Agrati**. An Inflammatory Profile Correlates With Decreased Frequency of Cytotoxic Cells in COVID-19. *Clin Infect Dis.* 2020 May 15;ciaa577. doi: 10.1093/cid/ciaa577.
 28. Albarello F, Pianura E, Di Stefano F, Cristofaro M, Petrone A, Marchioni L, Palazzolo C, Schininà V, Nicastrì E, Petrosillo N, Campioni P, Eskild P, Zumla A, Ippolito G; **COVID 19 INMI Study Group**. 2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation. *Int J Infect Dis.* 2020 Apr;93:192-197.
 29. Macchia I, La Sorsa V, Ruspantini I, Sanchez M, Tirelli V, Carollo M, Fedele G, Leone P, Schiavoni G, Buccione C, Rizza P, Nisticò P, Palermo B, Morrone S, Stabile H, Rughetti A, Nuti M, Zizzari IG, Fionda C, Maggio R, Capuano C, Quintarelli C, Sinibaldi M, **Agrati C**, Casetti R, Roza Gonzalez A, Iacobone F, Gismondi A, Belardelli F, Biffoni M, Urbani F. Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Naïve/Memory T Cell Immunomonitoring. *J Immunol Res.* 2020 Apr 12;2020:1938704.
 30. Bordoni V, Brando B, Piselli P, Forini O, Perna FE, Atripaldi U, Carputo S, Garziano F, Trento E, D'Agosto G, Latini A, Colafigli M, Cristaudo A, Sacchi A, Andreoni M, De Carli G, Orchi N, Grelli S, Gatti A, Cerva C, Minutolo A, Potestà M, Di Martino ML, Ortu F, Selva P, Del Pup L, Guarneri I, Lorenzini P, Capuano G, Antinori A, **Agrati C**. Naïve/Effector CD4 T cell ratio as a useful predictive marker of immune reconstitution in late presenter HIV patients: A multicenter study. *PLoS One.* 2019 Dec 23;14(12):e0225415. doi: 10.1371/journal.pone.0225415. eCollection 2019.
 31. **Agrati C**, Tumino N, Bordoni V, Pinnetti C, Sabatini A, Amendola A, Abbate I, Lorenzini P, Mondì A, Casetti R, Cimini E, Grassi G, Antinori A, Sacchi A. Myeloid Derived Suppressor Cells Expansion Persists After Early ART and May Affect CD4 T Cell Recovery. *Front Immunol.* 2019 Aug 8;10:1886. doi: 10.3389/fimmu.2019.01886. eCollection 2019.
 32. Nicastrì E, Vairo F, Mencarini P, Battisti A, **Agrati C**, Cimini E, Carrara S, D'Arezzo S, Adone R, Vulcano A, Iannetta M, Capone A, Petrosillo N, Fasanella A, Ippolito G. Unexpected human cases of cutaneous anthrax in Latium region, Italy, August 2017: integrated human-animal investigation of epidemiological, clinical, microbiological and ecological factors. *Italian Anthrax Team Members. Euro Surveill.* 2019 Jun;24(24):1800685. doi: 10.2807/1560-7917.ES.2019.24.24.1800685.
 33. Casetti R, Sacchi A, Bordoni V, Grassi G, Cimini E, Besi F, Pinnetti C, Mondì A, Antinori A, **Agrati C**. In Human Immunodeficiency Virus primary infection, early combined antiretroviral therapy reduced $\gamma\delta$ T-cell activation but failed to restore their polyfunctionality. *Immunology.* 2019 Aug;157(4):322-330. doi: 10.1111/imm.13089. Epub 2019 Jul 8.
 34. Bordoni V, Lalle E, Colavita F, Baiocchini A, Nardacci R, Falasca L, Carletti F, Cimini E, Bordini L, Kobinger G, D'Ambrosio V, Natale F, Giancotti A, Manganaro L, Del Nonno F, Zumla A, Liuzzi G, Ippolito G, Capobianchi MR, **Agrati C**, Castilletti C. Rescue of Replication-Competent ZIKV Hidden in Placenta-Derived Mesenchymal Cells Long After the Resolution of the Infection. *Open Forum Infect Dis.* 2019 Oct 9;6(10):ofz342. doi: 10.1093/ofid/ofz342. eCollection 2019 Oct.
 35. Scognamiglio P, Navarra A, Orchi N, De Carli G, Pittalis S, Mastroianni I, Visco Comandini U, **Agrati C**, Antinori A, Puro V, Ippolito G, Girardi E. Unawareness of HCV serostatus among persons newly diagnosed with HIV. *J Infect Public Health.* 2019 Feb 5. pii: S1876-0341(19)30057-7. doi: 10.1016/j.jiph.2019.01.055. [Epub ahead of print] PubMed PMID: 30737128.

36. Lapa D, **Agrati C**, Scognamiglio P, Cimini E, Capobianchi MR, Garbuglia AR. GB virus type C cross-reactivity in clinical samples with a low hepatitis C virus antibody positive response. *APMIS*. 2019 Feb;127(2):109-111. doi: 10.1111/apm.12921. PubMed PMID: 30698305.
37. Sacchi A, Tumino N, Grassi G, Casetti R, Cimini E, Bordoni V, Ammassari A, Antinori A, **Agrati C**. A new procedure to analyze polymorphonuclear myeloid derived suppressor cells in cryopreserved samples cells by flow cytometry. *PLoS One*. 2018 Aug 30;13(8):e0202920. doi: 10.1371/journal.pone.0202920. eCollection 2018. PubMed PMID: 30161175; PubMed Central PMCID: PMC6117014.
38. Colavita F, Bordoni V, Caglioti C, Biava M, Castilletti C, Bordi L, Quartu S, Iannetta M, Ippolito G, **Agrati C**, Capobianchi MR, Lalle E. ZIKV Infection Induces an Inflammatory Response but Fails to Activate Types I, II, and III IFN Response in Human PBMC. *Mediators Inflamm*. 2018 Jun 3;2018:2450540. doi: 10.1155/2018/2450540. eCollection 2018. PubMed PMID: 29967565; PubMed Central PMCID: PMC6008743.
39. Sacchi A, Tumino N, Sabatini A, Cimini E, Casetti R, Bordoni V, Grassi G, **Agrati C**. Myeloid-Derived Suppressor Cells Specifically Suppress IFN- γ Production and Antitumor Cytotoxic Activity of V δ 2 T Cells. *Front Immunol*. 2018 Jun 6;9:1271. doi: 10.3389/fimmu.2018.01271. eCollection 2018. PubMed PMID: 29928279; PubMed Central PMCID: PMC5997821.
40. Puro V, Fusco FM, Castilletti C, Carletti F, Colavita F, **Agrati C**, Di Caro A, Capobianchi MR, Ippolito G. Occupational transmission of an Orthopoxvirus infection during an outbreak in a colony of *Macaca tonkeana* in Lazio Region, Italy, 2015. *Zoonoses Public Health*. 2018 Mar 7. doi: 10.1111/zph.12459. [Epub ahead of print] PubMed PMID: 29512303.
41. Santangelo L, Bordoni V, Montaldo C, Cimini E, Zingoni A, Battistelli C, D'Offizi G, Capobianchi MR, Santoni A, Tripodi M, **Agrati C**. Hepatitis C virus direct-acting antivirals therapy impacts on extracellular vesicles microRNAs content and on their immunomodulating properties. *Liver Int*. 2018 Jan 22. doi: 10.1111/liv.13700. [Epub ahead of print] PubMed PMID: 29359389.
42. Bordoni V, Viola D, Sacchi A, Pinnetti C, Casetti R, Cimini E, Tumino N, Antinori A, Ammassari A, **Agrati C**. IL-18 and Stem Cell Factor affect hematopoietic progenitor cells in HIV-infected patients treated during primary HIV infection. *Cytokine*. 2018 Mar;103:34-37. doi: 10.1016/j.cyto.2017.12.033. Epub 2018 Jan 8. PubMed PMID: 29324258.
43. Tempestilli M, Fabbri G, Mastrorosa I, Timelli L, Notari S, Bellagamba R, Libertone R, Lupi F, Zaccarelli M, Antinori A, **Agrati C**, Ammassari A. Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world. *J Antimicrob Chemother*. 2018 Jan 1;73(1):160-164. doi: 10.1093/jac/dkx348. PubMed PMID:29106584.
44. Notari S, Tempestilli M, Fabbri G, Libertone R, Antinori A, Ammassari A, **Agrati C**. UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2017 Dec 12;1073:183-190. doi: 10.1016/j.jchromb.2017.12.018. [Epub ahead of print] PubMed PMID: 29276983.
45. Cimini E, Bordoni V, Sacchi A, Visco-Comandini U, Montalbano M, Taibi C, Casetti R, Lalle E, D'Offizi G, Capobianchi MR, **Agrati C**. Intrahepatic V γ 9V δ 2 T-cells from HCV-infected patients show an exhausted phenotype but can inhibit HCV replication. *Virus Res*. 2018 Jan 2;243:31-35. doi: 10.1016/j.virusres.2017.10.008. Epub 2017 Oct 10. PubMed PMID: 29029951.
46. Nicastri E, Brucato A, Petrosillo N, Biava G, Uyeki TM, Ippolito G; **INMI's Ebola Team**. Acute rhabdomyolysis and delayed pericardial effusion in an Italian patient with Ebola virus disease: a case report. *BMC Infect Dis*. 2017 Aug 30;17(1):597. doi: 10.1186/s12879-017-2689-x. PubMed PMID:

- 28854896; PubMed Central PMCID: PMC5576302.
47. Cimini E, Castilletti C, Sacchi A, Casetti R, Bordoni V, Romanelli A, Turchi F, Martini F, Tumino N, Nicastrì E, Corpolongo A, Di Caro A, Kobinger G, Zumla A, Capobianchi MR, Ippolito G, **Agrati C**. Human Zika infection induces a reduction of IFN- γ producing CD4 T-cells and a parallel expansion of effector V δ 2 T-cells. *Sci Rep*. 2017 Jul 24;7(1):6313. doi: 10.1038/s41598-017-06536-x. PubMed PMID: 28740159; PubMed Central PMCID: PMC5524759.
 48. Sacchi A, Tumino N, Turchi F, Refolo G, Fimia G, Ciccocanti F, Montalbano M, Lionetti R, Taibi C, D'Offizi G, Casetti R, Bordoni V, Cimini E, Martini F, **Agrati C**. Dendritic cells activation is associated with sustained virological response to telaprevir treatment of HCV-infected patients. *Clin Immunol*. 2017 Oct;183:82-90. doi: 10.1016/j.clim.2017.07.017. Epub 2017 Jul 20. PubMed PMID: 28736275.
 49. Cimini E, Viola D, Cabeza-Cabrerizo M, Romanelli A, Tumino N, Sacchi A, Bordoni V, Casetti R, Turchi F, Martini F, Bore JA, Koundouno FR, Duraffour S, Michel J, Holm T, Zekeng EG, Cowley L, Garcia Dorival I, Doerrbecker J, Hetzelt N, Baum JHJ, Portmann J, Wölfel R, Gabriel M, Miranda O, Díaz G, Díaz JE, Fleites YA, Piñeiro CA, Castro CM, Koivogui L, Magassouba N, Diallo B, Ruibal P, Oestereich L, Wozniak DM, Lüdtke A, Becker-Ziava B, Capobianchi MR, Ippolito G, Carroll MW, Günther S, Di Caro A, Muñoz-Fontela C, **Agrati C**. Different features of V δ 2 T and NK cells in fatal and non-fatal human Ebola infections. *PLoS Negl Trop Dis*. 2017 May 30;11(5):e0005645. doi: 10.1371/journal.pntd.0005645. eCollection 2017 May. PubMed PMID: 28558022; PubMed Central PMCID: PMC5472323.
 50. Colavita F, Biava M, Castilletti C, Quartu S, Vairo F, Caglioti C, **Agrati C**, Lalle E, Bordi L, Lanini S, Guanti MD, Miccio R, Ippolito G, Capobianchi MR, Di Caro A; Lazzaro Spallanzani Institute for Research and Health Care Ebola Virus Disease Sierra Leone Study Group. Measles Cases during Ebola Outbreak, West Africa, 2013-2106. *Emerg Infect Dis*. 2017 Jun;23(6):1035-1037. doi: 10.3201/eid2306.161682. PubMed PMID: 28518027; PubMed Central PMCID: PMC5443435.
 51. Casetti R, Pinnetti C, Sacchi A, De Simone G, Bordoni V, Cimini E, Tumino N, Besi F, Viola D, Turchi F, Mazzotta V, Antinori A, Martini F, Ammassari A, **Agrati C**. HIV-Specific CD8 T Cells Producing CCL-4 Are Associated With Worse Immune Reconstitution During Chronic Infection. *J Acquir Immune Defic Syndr*. 2017 Jul 1;75(3):338-344. doi: 10.1097/QAI.0000000000001392. PubMed PMID: 28418988.
 52. Tumino N, Casetti R, Fabbri G, Cimini E, Romanelli A, Turchi F, Forini O, Bordoni V, Antinori A, Ammassari A, Sacchi A, **Agrati C**. In HIV/HCV co-infected patients T regulatory and myeloid-derived suppressor cells persist after successful treatment with directly acting antivirals. *J Hepatol*. 2017 Apr 12. pii: S0168-8278(17)30207-6. doi: 10.1016/j.jhep.2017.03.036. [Epub ahead of print] PubMed PMID: 28411041.
 53. Bordoni V, Bibas M, Viola D, Sacchi A, Cimini E, Tumino N, Casetti R, Amendola A, Ammassari A, **Agrati C**, Martini F. Bone Marrow CD34(+) Progenitor Cells from HIV-Infected Patients Show an Impaired T Cell Differentiation Potential Related to Proinflammatory Cytokines. *AIDS Res Hum Retroviruses*. 2017 Jun;33(6):590-596 doi: 10.1089/AID.2016.0195. Epub 2017 Feb 22. PubMed PMID: 28125903.
 54. Tumino N, Bilotta MT, Pinnetti C, Ammassari A, Antinori A, Turchi F, **Agrati C**, Casetti R, Bordoni V, Cimini E, Abbate I, Capobianchi MR, Martini F, Sacchi A. Granulocytic Myeloid-Derived Suppressor Cells Increased in Early Phases of Primary HIV Infection Depending on TRAIL Plasma Level. *J Acquir Immune Defic Syndr*. 2017 Apr 15;74(5):575-582. doi: 10.1097/QAI.0000000000001283. PubMed PMID: 28060224.
 55. Bordoni V, Sacchi A, Cimini E, Casetti R, Tumino N, Ammassari A, **Agrati C**, Martini F. The Different Roles of Interleukin 7 and Interleukin 18 in Affecting Lymphoid Hematopoietic Progenitor Cells and CD4 Homeostasis in Naive Primary and Chronic HIV-Infected Patients. *Clin Infect Dis*. 2016 Dec

- 15;63(12):1683-1684. [IF 8.88]
56. Nicastrì E, Balestra P, Ricottini M, Petrosillo N, Di Caro A, Capobianchi MR, Giancola ML, Ippolito G; **INMI's Ebola Team**. Temporary neurocognitive impairment with Ebola virus. *J Neurol Neurosurg Psychiatry*. 2016 Jul 19. pii: jnnp-2016-313695. doi: 10.1136/jnnp-2016-313695. [IF 6.807]
 57. **Agrati C**, Castilletti C, Cimini E, Romanelli A, Lapa D, Quartu S, Martini F, Capobianchi MR. Antiviral activity of human V δ 2 T-cells against WNV includes both cytolytic and non-cytolytic mechanisms. *New Microbiol*. 2016 Apr;39(2):139-42. [IF 1.78]
 58. Ruibal P, Oestereich L, Lütke A, Becker-Ziaja B, et al. Unique human immune signature of Ebola virus disease in Guinea. *Nature*. 2016 May 5;533(7601):100-4. [IF 41.45]
 59. **Agrati C**, Castilletti C, Casetti R, Sacchi A, Falasca L, Turchi F, Tumino N, Bordoni V, Cimini E, Viola D, Lalle E, Bordini L, Lanini S, Martini F, Nicastrì E, Petrosillo N, Puro V, Piacentini M, Di Caro A, Kobinger GP, Zumla A, Ippolito G, Capobianchi MR. Longitudinal characterization of dysfunctional T cell-activation during human acute Ebola infection. *Cell Death Dis*. 2016 Mar 31;7:e2164. doi: 10.1038/cddis.2016.55. [IF 5.11]
 60. Bevilacqua N, Nicastrì E, Chinello P, Puro V, Petrosillo N, Di Caro A, Capobianchi MR, Lanini S, Vairo F, Pletschette M, Zumla A, Ippolito G; **INMI Ebola Team**. Criteria for discharge of patients with Ebola virus diseases in high-income countries. *Lancet Glob Health*. 2015 Dec;3(12):e739-40. PubMed PMID: 26608193. [IF 10.04]
 61. Salce L, Barbato S, Renna D, Bianchini F, Vaccaro P, Mazzeo F, Gasparini A, Rizza C, Lanfranchi E, Petrosillo N, Nicastrì E, Di Caro A, Capobianchi MR, Puro V, Ippolito G; **INMI EBOV Team**. First Italian Ebola virus disease case: management of hospital internal and external communication. *New Microbiol*. 2015 Oct;38(4):565-70. [IF 1.67]
 62. Petrosillo N, Nicastrì E, Lanini S, Capobianchi MR, Di Caro A, Antonini M, Puro V, Lauria FN, Shindo N, Magrini N, Kobinger GP, Ippolito G; **INMI EBOV Team**. Ebola virus disease complicated with viral interstitial pneumonia: a case report. *BMC Infect Dis*. 2015 Oct 16;15:432. doi: 10.1186/s12879-015-1169-4. [IF 3.11]
 63. Tumino N, Turchi F, Meschi S, Lalle E, Bordoni V, Casetti R, **Agrati C**, Cimini E, Montesano C, Colizzi V, Martini F, Sacchi A. In HIV-positive patients, myeloid-derived suppressor cells induce T-cell anergy by suppressing CD3 ζ expression through ELF-1 inhibition. *AIDS*. 2015 Nov 28;29(18):2397-407. [IF 6.55]
 64. Casetti R, De Simone G, Sacchi A, Rinaldi A, Viola D, **Agrati C**, Bordoni V, Cimini E, Tumino N, Besi F, Martini F. V γ 9V δ 2 T-Cell Polyfunctionality Is Differently Modulated in HAART-Treated HIV Patients according to CD4 T-Cell Count. *PLoS One*. 2015 Jul 10;10(7):e0132291. [IF 4.35]
 65. Cimini E, **Agrati C**, D'Offizi G, Vlasi C, Casetti R, Sacchi A, Lionetti R, Bordoni V, Tumino N, Scognamiglio P, Martini F. Primary and Chronic HIV Infection Differently Modulates Mucosal V δ 1 and V δ 2 T-Cells Differentiation Profile and Effector Functions. *PLoS One*. 2015 Jun 18;10(6):e0129771. doi: 10.1371/journal.pone.0129771. [IF 4.35]
 66. Tempestilli M, Pucci L, Notari S, Di Caro A, Castilletti C, Rivelli MR, **Agrati C**, Pucillo LP. Diagnostic performances of clinical laboratory tests using Triton X-100 to reduce the biohazard associated with routine testing of Ebola virus-infected patients. *Clin Chem Lab Med*. 2015 Nov;53(12):1967-73. [IF 3.00]
 67. Falasca L, **Agrati C**, Petrosillo N, Di Caro A, Capobianchi MR, Ippolito G, Piacentini M. Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. *Cell Death Differ*. 2015 Aug;22(8):1250-9. [IF 8.38]
 68. Bordoni V, Bibas M, Abbate I, Viola D, Rozera G, **Agrati C**, Rinaldi A, Amendola A, Ammassari A, Capobianchi MR, Martini F. Bone marrow CD34+ progenitor cells may harbour HIV-DNA even in successfully treated patients. *Clin Microbiol Infect*. 2015 Mar;21(3):290.e5-8. [IF 4.54]
 69. Bordoni V, Casetti R, Viola D, Abbate I, Rozera G, Sacchi A, Cimini E, Tumino

- N, **Agrati C**, Orchi N, Pinnetti C, Ammassari A, Martini F. Early ART in primary HIV infection may also preserve lymphopoiesis capability in circulating haematopoietic progenitor cells: a case report. *J Antimicrob Chemother.* 2015 May;70(5):1598-600. [IF 5.33]
70. **Agrati C**, Izzo L, Berno G, Cimini E, Bordoni V, Giancola ML, Baldini F, Colasanti M, Ettore GM, Izzo P, Pugliese F, Angrisani M, Di Cello P, Capobianchi MR, Bolognese A. JCV-specific T-cells producing IFN-gamma are differently associated with PmL occurrence in HIV patients and liver transplant recipients. *New Microbiol.* 2015 Jan;38(1):85-9. [IF 1.78]
71. Sacchi A, Rinaldi A, Tumino N, Casetti R, **Agrati C**, Turchi F, Bordoni V, Cimini E, Martini F. HIV Infection of Monocytes-Derived Dendritic Cells Inhibits V γ 9V δ 2 T Cells Functions. *PLoS One.* 2014 Oct 23;9(10). [IF 4.35]
72. Cimini E, Bordoni V, Lalle E, Montalbano M, Visco-Comandini U, Taibi C, D'Offizi G, Lionetti R, Scognamiglio P, Capobianchi MR, Martini F, **Agrati C**. Rapid and preemptive evaluation of individual anti-hepatitis C virus treatment outcome capability by a short-term autologous liver tissue culture system. *New Microbiol.* 2014 Jul;37(3):363-7. [IF 1.78]
73. **Agrati C**, Castillette C, Cimini E, Lapa D, Quartu S, Caglioti C, Lanini S, Cattoli G, Martini F, Ippolito G, Capobianchi MR. Cellular and humoral cross-immunity against two H3N2v influenza strains in presumably unexposed healthy and HIV-infected subjects. *PLoS One.* 2014 Aug 27;9(8). [IF 4.35]
74. Casetti R, De Simone G, Sacchi A, Bordoni V, Viola D, Rinaldi A, **Agrati C**, Gioia C, Martini F. Modulation of polyfunctional HIV-specific CD8 T cells in patients responding differently to antiretroviral therapy. *Int J Immunopathol Pharmacol.* 2014 Apr-Jun;27(2):291-7. [IF 2.99]
75. Capobianchi MR, Garbuglia AR, **Agrati C**, Rianda A, Noto P, Corpolongo A, Cataldo MA, Rosati S, Zaccaro P, Loffredo M, Pompa MG, Girardi E, Scognamiglio P, Ippolito G; GEAS Group. Molecular characterization of hepatitis A outbreak in the province of Rome, Lazio region, Italy, January-July 2013. *Microbes Infect.* 2014 Apr;16(4):362-6. [IF 2.80]
76. Baldini F, Baiocchini A, Schininà V, **Agrati C**, Giancola ML, Alba L, Grisetti S, Del Nonno F, Capobianchi MR, Antinori A. Brain localization of Kaposi's sarcoma in a patient treated by combination antiretroviral therapy. *BMC Infect Dis.* 2013 Dec 21;13:600. [IF 3.11]
77. Bordoni V, Bibas M, Viola D, Sacchi A, **Agrati C**, Castelli G, Ammassari A, Amendola A, Abbate I, Martini F. Chronic HIV-infected patients show an impaired dendritic cells differentiation of bone marrow CD34⁺ cells. *J Acquir Immune Defic Syndr.* 2013 Dec 1;64(4):342-4. [IF 4.56]
78. Bordoni V, Castelli G, Montesoro E, Federico M, Sacchi A, Morsilli O, **Agrati C**, Martini F, Chelucci C. HIV impairs CD34⁺-derived monocytic precursor differentiation into functional dendritic cells. *Int J Immunopathol Pharmacol.* 2013 Jul-Sep;26(3):717-24. [IF 2.99]
79. Cimini E, Bonnafous C, Sicard H, Vlassi C, D'Offizi G, Capobianchi MR, Martini F, **Agrati C**. In vivo interferon-alpha/ribavirin treatment modulates V γ 9V δ 2 T-cell function during chronic HCV infection. *J Interferon Cytokine Res.* 2013 Mar;33(3):136-41. [IF 3.20]
80. Bordoni V, Casetti R, Capuano G, De Stefani B, Piselli P, Gioia C, **Agrati C**, Martini F. A novel 8-color flow cytometry panel to study activation, maturation and senescence of CD4 and CD8 T lymphocytes in HIV-infected individuals at different stages of disease. *Int J Immunopathol Pharmacol.* 2012 Apr-Jun;25(2):415-24. [IF 2.99]
81. Cimini E, Bonnafous C, Bordoni V, Lalle E, Sicard H, Sacchi A, Berno G, Gioia C, D'Offizi G, Visco Comandini U, Vlassi C, Capobianchi MR, Martini F, **Agrati C**. Interferon- α improves phosphoantigen-induced V γ 9V δ 2 T-cells interferon- γ production during chronic HCV infection. *PLoS One.* 2012;7(5). [IF 4.35]
82. Bordoni V, **Agrati C**, Rinaldi A, Viola D, De Simone G, Gioia C, Martini F. In HIV-infected patients, some differential alterations of CD4 and CD8 T cell homeostasis may not be restored by ≥ 7 years of highly active antiretroviral therapy, in spite of good CD4 T cell repopulation. *J Antimicrob Chemother.*

- 2012 Jul;67(7):1802-4. [IF 5.33]
83. **Agrati C**, Gioia C, Castilletti C, Lapa D, Berno G, Puro V, Carletti F, Cimini E, Nisii C, Castellino F, Martini F, Capobianchi MR. Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients. *AIDS Res Hum Retroviruses*. 2012 Dec;28(12):1606-16. [IF 2.24]
 84. De Paolis P, Favaro A, Piola A, Martini F, Cristiana G, **Agrati C**, Iappelli M, Di Giulio S. "Immuknow" to measurement of cell-mediated immunity in renal transplant recipients undergoing short-term evaluation. *Transplant Proc*. 2011 May;43(4):1013-6. [IF 0.99]
 85. Cimini E, Piacentini P, Sacchi A, Gioia C, Leone S, Lauro GM, Martini F, **Agrati C**. Zoledronic acid enhances V δ 2 T-lymphocyte antitumor response to human glioma cell lines. *Int J Immunopathol Pharmacol*. 2011 Jan-Mar;24(1):139-48. [IF 2.99]
 86. **Agrati C**, D'Offizi G, Gougeon ML, Malkovsky M, Sacchi A, Casetti R, Bordoni V, Cimini E, Martini F. Innate gamma/delta T-cells during HIV infection: Terra relatively Incognita in novel vaccination strategies? *AIDS Rev*. 2011; 13(1):3-12. [IF 3.51]
 87. Sacchi A, **Agrati C**, D'Offizi G, Vlassi C, Rozera G, Abbate I, Capobianchi MR, Martini F. The basal activation state of DC subsets correlates with anti-HCV treatment outcome in HCV/HIV co-infected patients. *Clin Immunol*. 2011 Feb;138(2):178-86. [IF 4.04]
 88. **Agrati C**, Marianecchi C, Sennato S, Carafa M, Bordoni V, Cimini E, Tempestilli M, Pucillo LP, Turchi F, Martini F, Borioni G, Bordini F. Multicompartment vectors as novel drug delivery systems: selective activation of T $\gamma\delta$ lymphocytes after zoledronic acid delivery. *Nanomedicine*. 2011 Apr;7(2):153-61. [IF 5.05]
 89. Sacchi A, **Agrati C**, D'Offizi G, Vlassi C, Martini F. Co-stimulatory molecule CD80 expression may correlate with anti-HCV treatment outcome. *Gut*. 2011;60(8):1161-2. [IF 10.61]
 90. **Agrati C**, Gioia C, Lalle E, Cimini E, Castilletti C, Armignacco O, Lauria FN, Ferraro F, Antonini M, Ippolito G, Capobianchi MR, Martini F. Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course. *J Infect Dis*. 2010 Sep 1;202(5):681-9. [IF 5.77]
 91. Casetti R, **Agrati C**, Wallace M, Sacchi A, Martini F, Martino A, Rinaldi A, Malkovsky M. Cutting edge: TGF-beta1 and IL-15 Induce FOXP3+ gamma delta regulatory T cells in the presence of antigen stimulation. *J Immunol*. 2009; 15;183(6):3574-7. [IF 5.52]
 92. Poccia F, Gioia C, Martini F, Sacchi A, Piacentini P, Tempestilli M, **Agrati C**, Amendola A, Abdeddaim A, Vlassi C, Malkovsky M, D'Offizi G. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells. *AIDS*. 2009; Mar 13;23(5):555-65. [IF 6.55]
 93. **Agrati C**, Cimini E, Sacchi A, Bordoni V, Gioia C, Casetti R, Turchi F, Tripodi M, Martini F. Activated V gamma 9V delta 2 T cells trigger granulocyte functions via MCP-2 release. *J Immunol*. 2009; Jan 1;182(1):522-9. [IF 5.52]
 94. Sacchi A, Tempestilli M, Turchi F, **Agrati C**, Casetti R, Cimini E, Gioia C, Martini F. CD3zeta down-modulation may explain Vgamma9Vdelta2 T lymphocyte anergy in HIV-infected patients. *J Infect Dis*. 2009; Feb 1;199(3):432-6. [IF 5.77]
 95. Casetti R, Martino A, Sacchi A, **Agrati C**, Goletti D, Martini F. Do human gammadelta T cells respond to M tuberculosis protein antigens? *Blood*. 2008; 1;112(12):4776-7. [IF 10.55]
 96. Gioia C, **Agrati C**, Castilletti C, Capobianchi MR, Martini F. Influenza pandemics, immune cross-reactivity, and pandemic control strategies. *J Infect Dis*. 2008; Jul 15;198(2):294-5. [IF 5.77]
 97. Santini D, Martini F, Fratto ME, Galluzzo S, Vincenzi B, **Agrati C**, Turchi F, Piacentini P, Rocci L, Manavalan JS, Tonini G, Poccia F. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. *Cancer Immunol Immunother*. 2009; Jan;58(1):31-8. [IF 3.79]

98. Penitente R, Nicolò C, Van den Elzen P, Di Sante G, **Agrati C**, Aloisi F, Sercarz EE, Ria F. Administration of PLP139-151 primes T cells distinct from those spontaneously responsive in vitro to this antigen. *J Immunol.* 2008; May 15;180(10):6611-22. PubMed PMID: 18453580. [IF 5.52]
99. Gioia C, Castilletti C, Tempestilli M, Piacentini P, Bordi L, Chiappini R, **Agrati C**, Squarcione S, Ippolito G, Puro V, Capobianchi MR, Poccia F. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. *Emerg Infect Dis.* 2008 Jan;14(1):121-8. [IF 6.44]
100. **Agrati C.**, Volpi I, Martini F., Gioia C., Castilletti G., Ippolito G., Capobianchi MR., and Poccia F. Rapid and Biologically safe procedure for the evaluation of antigen-specific T cell response to microbial pathogens that may be used in BSL4 environment. *Applied Biosafety* 2008;
101. **Agrati C.**, Gioia C., Soldani F., Martini F., Antinori A., Poccia F. T cell selection and differentiation in AIDS disease: the model of HIV-discordant monozygotic twins. *J Biol Regul Homeost Agents.* 2008; 20(1-2):24-8 [IF: 0.99].
102. Nisii C, Tempestilli M, **Agrati C**, Poccia F, Tocci G, Longo MA, D'Offizi G, Tersigni R, Lo Iacono O, Antonucci G, Oliva A. Accumulation of dysfunctional effector CD8+T cells in the liver of patients with chronic HCV infection. *J Hepatol.* 2006; 44(3):475-483. [IF 4.931].
103. **Agrati C**, Alonzi T, De Santis R, Castilletti C, Abbate I, Capobianchi MR, D'Offizi G, Siepi F, Fimia GM, Tripodi M, Poccia F. Activation of V γ 9V δ 2 T cells by non-peptidic antigens induces the inhibition of subgenomic HCV replication. *Int Immunol.* 2006; 18(1):11-8. [IF: 3.317]
104. **Agrati C**, Castilletti C, De Santis R, Cimini E, Bordi L, Malkovsky M, Poccia F, Capobianchi MR. Interferon-gamma-mediated antiviral immunity against orthopoxvirus infection is provided by gamma delta T cells. *J. Infect. Dis.* 2006; 193: 1606. [IF: 4.953].
105. Poccia F., **Agrati C.**, Castilletti C., Bordi L., Gioia C., Horejsh D., Ippolito G. Chan PKS, Hui DSC, Sung JJY, Capobianchi M., Malkovsky M. Anti-SARS immunity: the role of V γ 9V δ 2 T lymphocytes. *J. Infect. Dis.* 2006; 193(9): 1244-9. [IF: 4.953].
106. Poccia F, **Agrati C**, Martini F, Mejia G, Wallace M, Malkovsky M. V γ 9V δ 2 T cell-mediated non-cytolytic antiviral mechanisms and their potential for cell-based therapy. *Immunol Lett.* 2005; 100(1):14-20. [IF: 2.301].
107. Martino A, Sacchi A, Volpe E, **Agrati C**, De Santis R, Pucillo LP, Colizzi V, Vendetti S. Non-Pathogenic Mycobacterium smegmatis induces the Differentiation of Human Monocytes directly into fully mature Dendritic Cells. *J. Clin. Immunol.* 2005; 25(4):365-75. [IF: 2.638]
108. Castilletti C, Bordi L, Lalle E, Rozera G, Poccia F, **Agrati C**, Abbate I, Capobianchi MR. Coordinate induction of IFN-alpha and -gamma by SARS-CoV also in the absence of virus replication. *Virology.* 2005; 341(1):163-9. [IF: 3.080]
109. **Agrati C**, Martini F, Nisii C, Oliva A, D'Offizi G, Narciso P, Nardacci R, Piacentini M, Dieli F, Pupillo LP, Poccia F. Preferential CD1d expression by hepatocytes resulting in a main restriction element for intrahepatic T-cell recognition. *J Biol Regul Homeost Agents.* 2005; 19(1-2):41-8. [IF: 0.99].
110. Martini F, **Agrati C**, D'Offizi G, Poccia F. HLA-E up-regulation induced by HIV infection may directly contribute to CD94-mediated impairment of NK cells. *Int J Immunopathol Pharmacol.* 2005; 18(2):269-76 [IF: 3.418].
111. Poccia F, **Agrati C**, Martini F, Capobianchi MR, Wallace M, Malkovsky M. Antiviral reactivities of gamma delta T cells. *Microbes Infect.* 2005 ;7(3):518-28. [IF: 3.154]
112. Martini F, Solmone M, **Agrati C**, Capobianchi MR, Iacomini F, Antonucci G, Poccia F. Influence of GB virus type C and HIV coinfection on gamma delta T cells. *Clin Infect Dis.* 2005; 40(2):326-8; [IF: 6.510]
113. Gioia C, Horejsh D, **Agrati C**, Martini F, Capobianchi MR, Ippolito G and Poccia F. T-cell response profiling to biological threat agents including the SARS Coronavirus. *Int J Immunopathol Pharmacol.* 2005; 1(3):525-30. [IF: 3.418]


114. Bordoni V, Alonzi T, **Agrati C**, Poccia F, Fimia GM, Piacentini M, Fantoni A and Tripodi M. (2004) "Stem cells differentiation towards NK cells induced by hepatocyte conditioned medium". *Immunology 2004 - International Proceedings Volume* ISBN 88-7587-069- [IF: 3.507]
115. Bordoni V, Alonzi T, **Agrati C**, Poccia F, Borsellino G, Mancino G, Fimia GM, Piacentini M, Fantoni A, Tripodi M. Murine hepatocyte cell lines promote expansion and differentiation of NK cells from stem cell precursors. *Hepatology*. 2004 Jun;39(6):1508-16. [IF: 9.792]
116. Alonzi T, **Agrati C**, Costabile B, Cicchini C, Amicone L, Cavallari C, Rocca CD, Folgori A, Fipaldini C, Poccia F, Monica NL, Tripodi M. Steatosis and intrahepatic lymphocyte recruitment in hepatitis C virus transgenic mice. *J Gen Virol*. 2004 Jun;85(Pt 6):1509-20. [IF: 3,013]
117. Cossarizza A., Poccia F., **Agrati C.**, D'Offizi G., Bugarini R., Pinti M., Bedini A., Borghi V., Mussini C., Esposito R., Ippolito G and Narciso P. Highly active antiretroviral therapy restores Vb T cell repertoire in patients with primary HIV infection but only qualitatively in naive HIV+ patients with chronic infection. *J Acquir Immune Defic Syndr*. 2004; 35(3):213-22. [IF: 3,871]
118. Gioia C., **Agrati C.**, Goletti D., Vincenti D., Carrara S., Amicosante M., Casarini M., Giosue S., Puglisi G., Rossi A., Colizzi V., Pucillo L.P., Poccia F. Different cytokine production and effector/memory dynamics of ab or gd T-cell subset in the peripheral blood of patients with active pulmonary tuberculosis. *International Journal of immunopathology and Pharmacology* 2003; 16(3):247-252. [IF: 3.418]
119. **Agrati C.**, Poccia F., Topino S., Narciso P., Selva C., Antonelli G., Bellomi F., Turriziani O., Bambacioni F., Pucillo L.P., and D'Offizi G. P-glycoprotein expression by peripheral mononuclear cells from HIV-infected patients is independent from HAART. *Clin Diagn Lab Immunol* 2003; 10(1):191-192. [IF: 2.056]
120. G. D'Offizi, C. Montesano, C. **Agrati, C.** Gioia, M. Amicosante, S. Topino, P. Narciso, L. P. Pucillo, G. Ippolito and F. Poccia. Expansion of pre-terminally differentiated CD8+ T-cells in chronic HIV+ patients presenting a rapid viral rebound during STI, *AIDS* 2002; 16:1-8. [IF: 5.835]
121. Poccia F. and **Agrati C.** Intrahepatic non-specific immunity and HCV immunopathogenesis. *Cell Death Differ*. 2003; 10 Suppl 1:S9-S12. [IF: 7.785]
122. **Agrati C**, C. Nisii, A. Oliva, G. D'Offizi, C. Montesano, L.P. Pucillo, F. Poccia. Lymphocytes distribution and intrahepatic compartmentalization during HCV infection: a main role of MHC-unrestricted T cells. *Arch Immunol Ther Exp* 2002; 50(5):307-16. [IF: 1.000]
123. Poccia F., Gougeon M.L., **Agrati C.**, Montesano C., Martini F., Pauza C.D., Fisch P., Wallace M., and Malkovsky M. Innate T-cell immunity in HIV infection: The role of Vg9Vd2 T lymphocytes. *Current Molecular Medicine* 2002; 2:485-505. [IF: 4.941]
124. F.Martini, F.Poccia, D.Goletti, S.Carrara, D.Vincenti, G.D'Offizi, C.Agrati, G.Ippolito, L.P.Pucillo, V.Colizzi and C.Montesano. Vg9Vd2 T cell impairments during viral rebound in chronic HIV-infected patients undergoing Structured Treatment Interruption. *J. Inf. Dis*. 2002; 186:847-850. [IF: 4.953]
125. D'Offizi G, Ciapparoni V, Gioia C., Goletti D., **Agrati C.**, Pucillo L.P., Narciso P. and Poccia F. The loss of CMV-specific CD27- T cell effectors in a patient with recurrences of CMV retinitis is independent of HIV-1 viremia. *Infection* 2002; 30:323-325. [IF: 1.854]
126. Gougeon ML, Malkovsky M, Casetti R, **Agrati C**, Poccia F. Innate T cell immunity to HIV-infection. Immunotherapy with phosphocarbohydrates, a novel strategy of immune intervention? *Vaccine* 2002; 20(15): 1938-41. [IF: 2.822]
127. Gioia C, **Agrati C**, Casetti R, Cairo C, Borsellino G, Battistini L, Mancino G, Goletti D, Colizzi V, Pucillo LP, Poccia F. Lack of CD27-CD45RA-V gamma 9 V delta 2+ T cell effectors in immunocompromised hosts and during active pulmonary tuberculosis. *J Immunol*. 2002; 168(3):1484-9. [IF: 6.387]
128. Montesano C, Gioia C, Martini F, **Agrati C**, Cairo C, Pucillo LP, Colizzi

- V, and Poccia F. Antiviral activity and anergy of gd T lymphocytes in cord blood and immunocompromised host. *J Biol Regul Homeost Agents*. 2001; 15 (3):257-64. [IF: 0,99]
129. **Agrati C.**, D'Offizi G., Narciso P., Selva C., Pucillo L.P., Ippolito G., Poccia F. gd T cell activation by chronic HIV infection may contribute to intrahepatic Vd1 compartmentalization and HCV-disease progression independently of HAART. *AIDS Research and Human Retrovirus* 2001; 17 (14): 1357-63. [IF: 2.531]
130. Poccia F, **Agrati C**, Ippolito G, Colizzi V and Malkovsky M. Natural T cell immunity to intracellular pathogens and nonpeptidic immunoregulatory drugs. *Current Molecular Medicine* 2001; 1:137-151. [IF: 4.941]
131. **Agrati C**, D'Offizi G, Narciso L, Abrignani S, Ippolito G, Colizzi V, and Poccia F. Vd1+ T Lymphocytes Expressing a Th1 phenotype Are the Major gd T Cell Subset Infiltrating the Liver of HCV-infected Persons. *Molecular Medicine* 2001; 7(1): 11-19. [IF: 3.349]
132. Biagioni S., Tata A.M., **Agrati C.**, Cianfarani F., Augusti-Tocco G. Modulation of cholinergic marker expression by nerve growth factor in dorsal root ganglia. *J. Neurosci. Res.* 2000; 62: 591-599. [IF: 3.239]
133. **Agrati C.**, Poccia F., and Colizzi V. Vaccinazione con antigeni non proteici. IV corso di biologia cellulare e molecolare in pneumologia. *Cuzzolin Editore*, 2000.
134. Tata A.M., Vilarò M.T., **Agrati C.**, Biagioni S., Mengod G., and Augusti-Tocco G. Expression of muscarinic m2 receptor mRNA in dorsal root ganglia of neonatal rat. *Brain Research* 1999; 824: 63-70. [IF: 2.296]

Driving license

Patente di guida A e B

Rome, 20/03/2021



“Autorizzo il trattamento dei miei dati personali ai sensi del Regolamento UE 2016/679